Source: Annual Congress 2008 - Clinical aspects of interstitial lung disease
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Chorostowska-Wynimko, A. Rozy, K. Lewandowska, M. Korzeniewska, J. Kus, M. Franczuk, A. Chcialowski, P. Kopinski (Warsaw, Poland). Procoagulant and antifibrynolitic activities strongly correlate with fibrosis and tissue turn-over markers in patients with active idiopathic pulmonary fibrosis and hypersensitivity pneumonitis. Eur Respir J 2008; 32: Suppl. 52, 3464

Member's Comments

No comment yet.

Related content which might interest you: The markers of inflammatory process activity and fybrogenesis activity in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2012 - Diffuse parenchymal lung disease I Year: 2012 Markers of fibrosis and tissue destruction in usual interstitial pneumonia associated with pulmonary emphysema Source: Eur Respir J 2007; 30: Suppl. 51, 489s Year: 2007 Increased levels of oxidative stress markers in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – Common mechanisms in lung development and fibrosis Year: 2016 Increased polysialylation in lung tissue of patients with idiopathic pulmonary fibrosis Source: Annual Congress 2011 - Cell biology of lung disease Year: 2011 Inhibition of local fibrinolysis differs between idiopathic pulmonary fibrosis (IPF) and fibrotic non-specific interstitial pneumonia (f-NSIP) Source: Annual Congress 2009 - Idiopathic pulmonary fibrosis: concepts and mechanisms Year: 2009 Distinguishing fibrotic hypersensitivity pneumonitis from idiopathic pulmonary fibrosis Source: International Congress 2019 – Lungs in the fog Year: 2019 Variable utility of mosaic attenuation to distinguish fibrotic hypersensitivity pneumonitis from idiopathic pulmonary fibrosis Source: Eur Respir J, 54 (1) 1900531; 10.1183/13993003.00531-2019 Year: 2019 Increased fibrinolytic mediators in IPF as potential contributors to pulmonary fibrosis and vascular remodeling Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Significance of histopathologic features suggesting connective tissue disease in idiopathic pulmonary fibrosis Source: International Congress 2015 – Connective tissue disorders Year: 2015 Clinical features of usual interstitial pneumonia-correlation between idiopathic pulmonary fibrosis and connective tissue disease associated with usual interstitial pneumonia Source: International Congress 2016 – Connective tissue disorders Year: 2016 Relationship between MIF and cellular pattern in BAL of patients with sarcoidosis, systemic sclerosis, idiopathic pulmonary fibrosis Source: Eur Respir J 2003; 22: Suppl. 45, 377s Year: 2003 Acute exercise in cystic fibrosis patients increases neutrophilic pulmonary inflammation Source: Annual Congress 2012 - Cystic fibrosis (adults and children): new basic and clinical physiology research Year: 2012 Coexistent pulmonary emphysema delays the decrease in vital capacity in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2008 - Miscellaneous aspects of interstitial lung disease Year: 2008 Aquoaporin-1 expression in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Neutrophil-rich inflammation in induced sputum of patients with idiopathic pulmonary fibrosis (IPF) Source: Eur Respir J 2001; 18: Suppl. 33, 409s Year: 2001 Tumor-associated antigens in acute exacerbation of idiopathic pulmonary fibrosis: Associations with disease activity Source: Annual Congress 2010 - Clinical aspects in pulmonary fibrosis Year: 2010 Differences of acute exacerbations in idiopathic pulmonary fibrosis compared to other fibrotic lung diseases Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis Year: 2019 17(R)-resolvinD1 improves MMP-9/TIMP-1 imbalance leading to amelioration of pulmonary fibrosis in mice Source: International Congress 2016 – ILD pathogenesis Year: 2016 Relationship between nintedanib exposure and adverse events in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF treatment II Year: 2016 Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015